Stock OCS OCULIS HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

Oculis Holding AG Stock

Equities

OCS

CH1242303498

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
11.95 USD -0.25% Intraday chart for Oculis Holding AG +1.44% +6.41%
Apr. 24 H.C. Wainwright Adjusts Price Target on Oculis Holding to $28 From $29, Keeps Buy Rating MT
Apr. 24 Oculis Holding AG(NasdaqGM:OCS) added to OMX Nordic All-Share Index CI

Financials

Sales 2024 * 914K 999K Sales 2025 * 10.9M 11.92M Capitalization 458M 501M
Net income 2024 * -58M -63.42M Net income 2025 * -72M -78.72M EV / Sales 2024 * 414 x
Net cash position 2024 * 79.97M 87.43M Net cash position 2025 * 25.15M 27.49M EV / Sales 2025 * 39.7 x
P/E ratio 2024 *
-7.01 x
P/E ratio 2025 *
-6.15 x
Employees 36
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.76%
More Fundamentals * Assessed data

Chart Oculis Holding AG

Dynamic Chart

Latest news about Oculis Holding AG

H.C. Wainwright Adjusts Price Target on Oculis Holding to $28 From $29, Keeps Buy Rating MT
Oculis Holding AG(NasdaqGM:OCS) added to OMX Nordic All-Share Index CI
Oculis Completes $59 Million Direct Offering of Shares MT
Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development CI
Oculis Holding Ag Announces Positive Results from Phase 3 Optimize-1 Trial of Once Daily Ocs-01 for the Treatment of Inflammation and Pain Following Cataract Surgery CI
Oculis Holding Files $300 Million Mixed-Securities Shelf Registration MT
Baird Adjusts Price Target on Oculis to $35 From $64, Maintains Outperform Rating MT
Oculis Narrows Q4 Loss, Improves Cash Position -- Shares Fall MT
Oculis Holding AG Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Oculis Holding AG Announces Executive Appointments CI
Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery CI
Oculis Holding AG Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema CI
Oculis Evaluating First Patient in Phase 2b Trial MT
Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNF ALPHA> Licaminlimab (OCS-02) in Dry Eye Disease CI
Chardan Initiates Oculis Holding With Buy Rating, Price Target is $30 MT
More news

Analyst Recommendations on Oculis Holding AG

H.C. Wainwright Adjusts Price Target on Oculis Holding to $28 From $29, Keeps Buy Rating MT
Baird Adjusts Price Target on Oculis to $35 From $64, Maintains Outperform Rating MT
Chardan Initiates Oculis Holding With Buy Rating, Price Target is $30 MT
Stifel Initiates Oculis With Buy Rating, Price Target is $35 MT
Wedbush Adjusts Oculis Price Target to $29 From $31, Maintains Outperform Rating MT
More recommendations

Press releases Oculis Holding AG

Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market GL
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market AQ
Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development AQ
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting AQ
Oculis to Participate at Upcoming April Investor Conferences AQ
More press releases

Quotes and Performance

1 day-0.25%
1 week+1.44%
Current month-0.83%
1 month+2.93%
3 months-9.81%
6 months+24.87%
Current year+6.41%
More quotes

Highs and lows

1 week
11.72
Extreme 11.72
12.45
1 month
10.55
Extreme 10.55
12.45
Current year
10.11
Extreme 10.105
14.47
1 year
9.05
Extreme 9.05
14.50
3 years
6.26
Extreme 6.26
14.50
5 years
6.26
Extreme 6.26
14.50
10 years
6.26
Extreme 6.26
14.50
More quotes

Managers and Directors - Oculis Holding AG

Managers TitleAgeSince
Riad Sherif CEO
 Chief Executive Officer 56 17-11-30
Sylvia Cheung DFI
 Director of Finance/CFO 50 20-08-31
Ramin Tadayoni CTO
 Chief Tech/Sci/R&D Officer 54 Feb. 27
Members of the board TitleAgeSince
Anthony Adam Rosenberg CHM
 Chairman 71 18-03-31
Martijn Kleijwegt BRD
 Director/Board Member 69 23-03-02
Geraldine O'Keeffe BRD
 Director/Board Member 58 23-03-02
More insiders

Quotes

Date Price Change Volume
24-04-26 12.02 +0.59% 88,399
24-04-25 11.95 -0.25% 25,315
24-04-24 11.98 +0.08% 191,128
24-04-23 11.97 +0.17% 306,321
24-04-22 11.95 +1.44% 188,480

End-of-day quote Nasdaq, April 24, 2024

More quotes

Company Profile

Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Sector
Biotechnology & Medical Research
More about the company

Income Statement Evolution

More financial data

Ratings for Oculis Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
10.99 CHF
Average target price
25.49 CHF
Spread / Average Target
+131.85%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
OCULIS HOLDING AG Stock Oculis Holding AG
+6.41% 501M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. OCS Stock